دورية أكاديمية
أعرض في EDS

Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma.

التفاصيل البيبلوغرافية
العنوان: Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma.
المؤلفون: Maddison K; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.; Centre for Drug Repurposing and Medicines Research, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Graves MC; School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia.; Centre for Drug Repurposing and Medicines Research, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Bowden NA; School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia.; Centre for Drug Repurposing and Medicines Research, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Fay M; School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia.; Centre for Drug Repurposing and Medicines Research, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.; GenesisCare, Lake Macquarie Private Hospital, Gateshead, NSW, Australia., Vilain RE; School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Cancer Biobank, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.; Pathology North, Hunter New England Area Health Service, New Lambton Heights, NSW, Australia., Faulkner S; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Tooney PA; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.; Centre for Drug Repurposing and Medicines Research, The University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
المصدر: Oncotarget [Oncotarget] 2021 Oct 12; Vol. 12 (21), pp. 2177-2187. Date of Electronic Publication: 2021 Oct 12 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مستخلص: Immunotherapies targeting tumour-infiltrating lymphocytes (TILs) that express the immune checkpoint molecule programmed cell death-1 (PD-1) have shown promise in preclinical glioblastoma models but have had limited success in clinical trials. To assess when glioblastoma is most likely to benefit from immune checkpoint inhibitors we determined the density of TILs in primary and recurrent glioblastoma. Thirteen cases of matched primary and recurrent glioblastoma tissue were immunohistochemically labelled for CD3, CD8, CD4 and PD-1, and TIL density assessed. CD3+ TILs were observed in all cases, with the majority of both primary (69.2%) and recurrent (61.5%) tumours having low density of TILs present. CD8+ TILs were observed at higher densities than CD4+ TILs in both tumour groups. PD-1+ TILs were sparse and present in only 25% of primary and 50% of recurrent tumours. Quantitative analysis of TILs demonstrated significantly higher CD8+ TIL density at recurrence ( p = 0.040). No difference was observed in CD3+ ( p = 0.191), CD4+ ( p = 0.607) and PD-1+ ( p = 0.070) TIL density between primary and recurrent groups. This study shows that TILs are present at low densities in both primary and recurrent glioblastoma. Furthermore, PD-1+ TILs were frequently absent, which may provide evidence as to why anti-PD-1 immunotherapy trials have been largely unsuccessful in glioblastoma.
Competing Interests: CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
(Copyright: © 2021 Maddison et al.)
References: J Pathol Transl Med. 2017 Jan;51(1):40-48. (PMID: 27989100)
Acta Neuropathol. 2013 Oct;126(4):525-35. (PMID: 23880787)
Neuro Oncol. 2006 Jul;8(3):261-79. (PMID: 16775224)
Nat Med. 2019 Mar;25(3):477-486. (PMID: 30742122)
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1423-6. (PMID: 16029802)
Br J Cancer. 2015 Jul 14;113(2):232-41. (PMID: 26125449)
J Neurooncol. 2019 Jun;143(2):241-249. (PMID: 31025274)
Neuro Oncol. 2016 Oct;18(10):1357-66. (PMID: 27370400)
Cancer Immunol Immunother. 2017 Mar;66(3):379-389. (PMID: 27942839)
Nat Immunol. 2007 Mar;8(3):239-45. (PMID: 17304234)
Nat Med. 2018 Sep;24(9):1459-1468. (PMID: 30104766)
Elife. 2018 Sep 04;7:. (PMID: 30179157)
J Neurooncol. 2016 Sep;129(3):453-460. (PMID: 27377654)
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. (PMID: 23462419)
Clin Cancer Res. 2011 Jul 1;17(13):4296-308. (PMID: 21478334)
Front Immunol. 2020 May 07;11:835. (PMID: 32457755)
Br J Cancer. 2014 May 13;110(10):2560-8. (PMID: 24691423)
Clin Cancer Res. 2017 Jan 1;23(1):124-136. (PMID: 27358487)
J Clin Neurosci. 2010 Nov;17(11):1381-5. (PMID: 20727764)
J Neurooncol. 2017 Jul;133(3):561-569. (PMID: 28500559)
Front Oncol. 2018 Dec 05;8:578. (PMID: 30568917)
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. (PMID: 32437507)
Sci Transl Med. 2012 Mar 28;4(127):127ra37. (PMID: 22461641)
Neuro Oncol. 2010 Jul;12(7):631-44. (PMID: 20179016)
Int J Cancer. 2017 Nov 1;141(9):1891-1900. (PMID: 28681455)
Blood. 2009 Aug 20;114(8):1537-44. (PMID: 19423728)
Sci Immunol. 2019 Jul 12;4(37):. (PMID: 31300479)
Surg Neurol. 1985 Mar;23(3):221-6. (PMID: 2983448)
N Engl J Med. 2015 Jan 22;372(4):320-30. (PMID: 25399552)
Neuro Oncol. 2016 Feb;18(2):195-205. (PMID: 26323609)
Oncotarget. 2017 Oct 6;8(53):91779-91794. (PMID: 29207684)
J Clin Invest. 2014 Mar;124(3):1228-41. (PMID: 24569378)
Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505)
Cancer Immunol Res. 2016 Feb;4(2):124-35. (PMID: 26546453)
Neuro Oncol. 2015 Aug;17(8):1064-75. (PMID: 25355681)
N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174)
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8389-94. (PMID: 12829791)
Clin Cancer Res. 2018 Sep 1;24(17):4187-4200. (PMID: 29444930)
JAMA. 2013 Nov 6;310(17):1842-50. (PMID: 24193082)
Cell. 2020 Jun 25;181(7):1643-1660.e17. (PMID: 32470396)
Front Immunol. 2017 Nov 07;8:1451. (PMID: 29163521)
Lab Invest. 2014 Jan;94(1):107-16. (PMID: 24217091)
Oncoimmunology. 2018 Oct 16;8(1):e1525243. (PMID: 30546966)
Clin Cancer Res. 2011 Aug 15;17(16):5473-80. (PMID: 21737504)
J Neurooncol. 2007 Nov;85(2):133-48. (PMID: 17874037)
J Neurooncol. 2017 Mar;132(1):35-44. (PMID: 28102487)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
J Immunother Cancer. 2018 Jan 25;6(1):4. (PMID: 29368638)
Brain. 2001 Mar;124(Pt 3):480-92. (PMID: 11222448)
فهرسة مساهمة: Keywords: glioblastoma; immune microenvironment; programmed cell death 1; tumour recurrence; tumour-infiltrating lymphocytes
تواريخ الأحداث: Date Created: 20211022 Latest Revision: 20211023
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8522837
DOI: 10.18632/oncotarget.28069
PMID: 34676050
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.28069